Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11526524rdf:typepubmed:Citationlld:pubmed
pubmed-article:11526524lifeskim:mentionsumls-concept:C0439861lld:lifeskim
pubmed-article:11526524lifeskim:mentionsumls-concept:C0054201lld:lifeskim
pubmed-article:11526524lifeskim:mentionsumls-concept:C0039593lld:lifeskim
pubmed-article:11526524lifeskim:mentionsumls-concept:C0079240lld:lifeskim
pubmed-article:11526524lifeskim:mentionsumls-concept:C0031082lld:lifeskim
pubmed-article:11526524lifeskim:mentionsumls-concept:C0994894lld:lifeskim
pubmed-article:11526524pubmed:issue3lld:pubmed
pubmed-article:11526524pubmed:dateCreated2001-8-29lld:pubmed
pubmed-article:11526524pubmed:abstractTextBudesonide, a marker for corticosteroid allergy, is a 1:1 mixture of 2 diastereomers, the R and S, present in all commercial formulations. Budesonide is said to cross-react with group B substances through the R and S diastereomer and some group D substances only through the S diastereomer.lld:pubmed
pubmed-article:11526524pubmed:languageenglld:pubmed
pubmed-article:11526524pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11526524pubmed:citationSubsetIMlld:pubmed
pubmed-article:11526524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11526524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11526524pubmed:statusMEDLINElld:pubmed
pubmed-article:11526524pubmed:monthSeplld:pubmed
pubmed-article:11526524pubmed:issn1046-199Xlld:pubmed
pubmed-article:11526524pubmed:authorpubmed-author:BruzeMMlld:pubmed
pubmed-article:11526524pubmed:authorpubmed-author:IsakssonMMlld:pubmed
pubmed-article:11526524pubmed:authorpubmed-author:GoossensAAlld:pubmed
pubmed-article:11526524pubmed:authorpubmed-author:LepoittevinJ...lld:pubmed
pubmed-article:11526524pubmed:copyrightInfoCopyright 2001 by W.B. Saunders Companylld:pubmed
pubmed-article:11526524pubmed:issnTypePrintlld:pubmed
pubmed-article:11526524pubmed:volume12lld:pubmed
pubmed-article:11526524pubmed:ownerNLMlld:pubmed
pubmed-article:11526524pubmed:authorsCompleteYlld:pubmed
pubmed-article:11526524pubmed:pagination170-6lld:pubmed
pubmed-article:11526524pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:meshHeadingpubmed-meshheading:11526524...lld:pubmed
pubmed-article:11526524pubmed:year2001lld:pubmed
pubmed-article:11526524pubmed:articleTitlePatch testing with serial dilutions of budesonide, its R and S diastereomers, and potentially cross-reacting substances.lld:pubmed
pubmed-article:11526524pubmed:affiliationDepartment of Occupational and Environmental Dermatology, Malmö University Hospital, Malmö, Sweden.lld:pubmed
pubmed-article:11526524pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11526524pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed